Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Real-World study tracks brain tumor patients on vorasidenib

NCT ID NCT07240662

First seen Nov 21, 2025 · Last updated Jun 22, 2026 · Updated 28 times

Summary

This study follows 150 adults with IDH-mutant grade 2 glioma who are taking vorasidenib after surgery. Researchers will track quality of life, seizure control, and tumor response in everyday clinical practice. The goal is to understand how well the drug works outside of strict trial settings.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg

    RECRUITING

    Heidelberg, Germany

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Vorasidenib

What this could lead to

If successful, this study could show how vorasidenib affects daily life and seizures in routine care, helping doctors and patients make better treatment decisions.

What could go wrong

This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be limited by the small number of participants and lack of a comparison group.

Conditions

The condition(s) this trial relates to.

glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.